Evotec announces science chief exit as Evotec stock sits 60.96 percent below its high

Published on 10/09/2026 at 13:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue fell 16.21 percent to EUR 143.48 million in second quarter 2026. Evotec stock costs EUR 2.85 on October 9, 2026 versus EUR 2.83, plus 0.71 percent.

Key points in brief

Evotec announced on September 29, 2026 that Chief Scientific Officer Cord Dohrmann would leave effective September 30 after 16 years.
Second-quarter 2026 revenue fell 16.21 percent to EUR 143.48 million from EUR 171.24 million.
The Lang & Schwarz price was EUR 2.85 on October 9, 2026 at 1:05 p.m. CEST, plus 0.71 percent versus EUR 2.83.
Evotec's third-quarter 2026 statement is scheduled for November 5, 2026.

3D-Architekturvisualisierung eines modernen Glas-Forschungscampus mit begrüntem Innenhof — Architektur-Render eines modernen Forschungscampus veranschaulicht den Biotech-Standort von Evotec SE, ISIN DE0005664809, glasklar gestaltet, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) announced on September 29, 2026 that Chief Scientific Officer Cord Dohrmann would leave effective September 30 after 16 years, while the stock was EUR 2.85 at Lang & Schwarz on October 9, 2026, 60.96 percent below its EUR 7.30 52-week high. The leadership change adds a strategic question to a business already facing lower revenue expectations.

Three dated milestones shape the story

On August 13, 2026, Evotec reported second-quarter 2026 revenue of EUR 143.48 million, down 16.21 percent from EUR 171.24 million, according to finanzen.ch.

On September 15, 2026, Evotec lowered its 2026 revenue outlook to EUR 570 million-EUR 610 million from EUR 700 million-EUR 780 million, while adjusted EBITDA guidance moved to a loss of EUR 70 million-EUR 105 million, according to Börse Express.

On September 29, 2026, the company announced that Dohrmann would step down after 16 years as chief scientific officer, with a successor search underway, according to PR Newswire.

What does the outlook mean for revenue

The revised revenue range places the upper end EUR 170 million below the former ceiling and the lower end EUR 130 million below the former floor. That reset matters because second-quarter revenue of EUR 143.48 million represented only one quarter of the new full-year range, while the first-half 2026 revenue cited in the same coverage was EUR 300.10 million.

The operating picture remains loss-making. Börse Express reported adjusted EBITDA of minus EUR 42.70 million for the first half of 2026, alongside the new full-year adjusted EBITDA loss guidance of EUR 70 million-EUR 105 million. The figures make execution of the Horizon savings program and delivery from Evotec's drug-discovery partnerships central to the next reporting cycle.

Next date is November 5

Evotec's next substantiated reporting date is November 5, 2026, when the company is scheduled to publish its third-quarter 2026 statement, according to EQS News. That release will provide the next quantified test of whether quarterly revenue can support the reduced annual range.

Stock stays below EUR 3.00

Berenberg kept a Hold rating and a EUR 3.60 price target on September 25, 2026 after a discussion with Chief Executive Officer Christian Wojczewski, according to FinanzNachrichten.de. Against the EUR 2.85 Lang & Schwarz price, that target is 26.32 percent higher, although the analyst cited commercial repositioning and delayed milestones as constraints on revenue visibility.

Evotec was trading at EUR 2.85 at Lang & Schwarz on October 9, 2026 at 1:05 p.m. CEST, plus 0.71 percent versus the EUR 2.83 prior close of October 8, 2026. The 52-week range was EUR 2.71 to EUR 7.30 as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.